Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Non-Current Liabilities: 2020-2023

Historic Other Non-Current Liabilities for Kymera Therapeutics (KYMR) over the last 3 years, with Sep 2023 value amounting to $8,000.

  • Kymera Therapeutics' Other Non-Current Liabilities fell 96.88% to $8,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $8,000, marking a year-over-year decrease of 96.88%. This contributed to the annual value of $248,000 for FY2022, which is 275.76% up from last year.
  • Latest data reveals that Kymera Therapeutics reported Other Non-Current Liabilities of $8,000 as of Q3 2023, which was down 96.52% from $230,000 recorded in Q2 2023.
  • Kymera Therapeutics' 5-year Other Non-Current Liabilities high stood at $273,000 for Q1 2022, and its period low was $8,000 during Q3 2023.
  • Over the past 3 years, Kymera Therapeutics' median Other Non-Current Liabilities value was $230,000 (recorded in 2023), while the average stood at $166,727.
  • In the last 5 years, Kymera Therapeutics' Other Non-Current Liabilities skyrocketed by 275.76% in 2022 and then tumbled by 96.88% in 2023.
  • Quarterly analysis of 4 years shows Kymera Therapeutics' Other Non-Current Liabilities stood at $100,000 in 2020, then crashed by 34.00% to $66,000 in 2021, then skyrocketed by 275.76% to $248,000 in 2022, then crashed by 96.88% to $8,000 in 2023.
  • Its last three reported values are $8,000 in Q3 2023, $230,000 for Q2 2023, and $237,000 during Q1 2023.